Metabolic rewiring and serotonin depletion in patients with postacute sequelae of COVID-19 - PubMed (original) (raw)

. 2022 May;77(5):1623-1625.

doi: 10.1111/all.15253. Epub 2022 Feb 17.

Affiliations

Metabolic rewiring and serotonin depletion in patients with postacute sequelae of COVID-19

Corinna Sadlier et al. Allergy. 2022 May.

No abstract available

Keywords: COVID; basic immunology; lung diseases other than asthma and COPD.

PubMed Disclaimer

Conflict of interest statement

LOM is a consultant to PrecisionBiotics and has received research funding from GSK and Chiesi. LOM has participated in speaker's bureau for Nestle, Nutricia, Reckitt, and Abbott. WCA has participated in advisory boards for Pfizer, MSD, and Sanofi, with reimbursements paid to his institution. None of the other authors report any conflict of interest.

Figures

FIGURE 1

FIGURE 1

Principal component analysis of serum metabolite levels in healthy volunteers (Controls, n = 20) and PASC patients (n = 20) at 4–6 months (T1) and 6–9 months (T2) following hospital discharge

FIGURE 2

FIGURE 2

Violin plots illustrating the differences in specific serum metabolite levels in healthy volunteers (Controls, n = 20) and PASC patients (n = 20) at 4–6 months (T1) and 6–9 months (T2) following hospital discharge. Statistical significance was determined using one‐way ANOVA and Tukey’s multiple comparison test

Similar articles

Cited by

References

    1. World Health Organization . A clinical case definition of post COVID‐19 condition by a Delphi consensus. Published Online October 6, 2021. https://www.who.int/publications/i/item/WHO‐2019‐nCoV‐Post_COVID‐19_cond...
    1. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019 - DOI - PMC - PubMed
    1. Ahearn‐Ford S, Lunjani N, McSharry B, et al. Long‐term disruption of cytokine signalling networks is evident in patients who required hospitalization for SARS‐CoV‐2 infection. Allergy. 2021;76(9):2910‐2913. doi:10.1111/all.14953 - DOI - PMC - PubMed
    1. Albrich WC, Ghosh TS, Ahearn‐Ford S, et al. A high‐risk gut microbiota configuration associates with hyperinflammatory immune and metabolic responses to acute SARS‐CoV‐2 infection. Preprint: https://biorxiv.org/cgi/content/short/2021.10.26.465865v1 - PMC - PubMed
    1. Reis G, dos Santos Moreira‐Silva EA, Medeiros‐Silva DC, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID‐19: The TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42‐e51. doi:10.1016/S2214-109X(21)00448-4. (published online Oct 27.). - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources